NO995033L - 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine - Google Patents

6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine

Info

Publication number
NO995033L
NO995033L NO995033A NO995033A NO995033L NO 995033 L NO995033 L NO 995033L NO 995033 A NO995033 A NO 995033A NO 995033 A NO995033 A NO 995033A NO 995033 L NO995033 L NO 995033L
Authority
NO
Norway
Prior art keywords
compound
administering
effective amount
therapeutically effective
aminopyrido
Prior art date
Application number
NO995033A
Other languages
Norwegian (no)
Other versions
NO995033D0 (en
Inventor
Shripad S Bhagwat
Chih-Hung Lee
Richard J Perner
Yu-Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO995033D0 publication Critical patent/NO995033D0/en
Publication of NO995033L publication Critical patent/NO995033L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelse som har formel (I): R1^X ro hvor R1, R2, R3 og R4 er definerte variabler valgt fra gruppene som spesifisert her, hvilke inkluderer alkyl, aryl, heteroaryl og heterosyklyl, og substituerte versjoner derav, en fremgangsmåte ved inhibering av adenosinkinase ved å administrere en forbindelse derav, en farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av en forbindelse derav ovenfor, i kombinasjon med en farma- søytisk akseptabel bærer, en fremgangsmåte ved behandling av cerebral iskemi, epilepsi nocipersepsjon, smerte, inflammasjon og sepsis i et pattedyr som trenger slik behandling, omfattende å administrere til pattedyret en terapeutisk effektiv mengde av en forbindelse derav, og fremgangsmåter ved fremstilling derav.Compound having Formula (I): R 1 X X wherein R 1, R 2, R 3 and R 4 are defined variables selected from the groups as specified herein which include alkyl, aryl, heteroaryl and heterocyclyl, and substituted versions thereof, a method of inhibiting adenosine kinase by administering a compound thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above, in combination with a pharmaceutically acceptable carrier, a method of treating cerebral ischemia, epilepsy nociception, pain, inflammation and sepsis in a mammals in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, and methods of preparing them.

NO995033A 1997-04-16 1999-10-15 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine NO995033L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83439397A 1997-04-16 1997-04-16
PCT/US1998/004127 WO1998046603A1 (en) 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
NO995033D0 NO995033D0 (en) 1999-10-15
NO995033L true NO995033L (en) 1999-12-15

Family

ID=25266829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995033A NO995033L (en) 1997-04-16 1999-10-15 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine

Country Status (20)

Country Link
EP (1) EP0979230A1 (en)
JP (1) JP2001520649A (en)
KR (1) KR20010006453A (en)
CN (1) CN1259948A (en)
AR (1) AR012435A1 (en)
AU (1) AU744528B2 (en)
BG (1) BG103861A (en)
BR (1) BR9809088A (en)
CA (1) CA2287465A1 (en)
CO (1) CO4940439A1 (en)
HU (1) HUP0001402A3 (en)
IL (1) IL131892A0 (en)
NO (1) NO995033L (en)
NZ (1) NZ337844A (en)
PL (1) PL336262A1 (en)
SK (1) SK142099A3 (en)
TR (1) TR199902456T2 (en)
TW (1) TW458977B (en)
WO (1) WO1998046603A1 (en)
ZA (1) ZA982912B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
BRPI0207172B8 (en) * 2001-02-12 2021-05-25 Hoffmann La Roche 6-substituted pyrido-pyrimidines, their composition and use, as well as their intermediate
EP1824861A2 (en) 2004-11-12 2007-08-29 Trustees of the Tufts College Lipase inhibitors
WO2008121257A1 (en) * 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
EA201590693A1 (en) * 2012-10-05 2015-08-31 Ригель Фармасьютикалс, Инк. INHIBITORS GDF-8
WO2017205848A1 (en) * 2016-05-27 2017-11-30 Legacy Emanuel Hospital & Health Center Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
TR199902456T2 (en) 2000-07-21
KR20010006453A (en) 2001-01-26
WO1998046603A1 (en) 1998-10-22
BG103861A (en) 2000-06-30
ZA982912B (en) 1998-10-09
PL336262A1 (en) 2000-06-19
TW458977B (en) 2001-10-11
CN1259948A (en) 2000-07-12
CO4940439A1 (en) 2000-07-24
EP0979230A1 (en) 2000-02-16
NZ337844A (en) 2001-11-30
HUP0001402A3 (en) 2001-01-29
AU7098198A (en) 1998-11-11
AU744528B2 (en) 2002-02-28
HUP0001402A2 (en) 2000-10-28
CA2287465A1 (en) 1998-10-22
NO995033D0 (en) 1999-10-15
SK142099A3 (en) 2000-05-16
JP2001520649A (en) 2001-10-30
BR9809088A (en) 2000-08-01
IL131892A0 (en) 2001-03-19
AR012435A1 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
EA200100135A1 (en) ALKINYL SUBSTITUTED DERIVATIVES OF QUINOLIN-2-SHE USEFUL AS ANTI-TREATMENT AGENTS
RU94044671A (en) Use of nonpeptide antagonists of tachykinin receptors
NO175592C (en) Analogous Process for the Preparation of Therapeutically Active Xanthines
WO1999032477B1 (en) Ortho-anthranilamide derivatives as anti-coagulants
WO1996013512B1 (en) L-ribofuranosyl nucleosides
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
ATE164575T1 (en) SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS
WO2003048164A3 (en) Adenosine a2a receptor antagonists
RU94022743A (en) Amido and carbamido derivatives having antihypercholesteric activity, preparation thereof, and therapeutic use thereof
NO995036L (en) 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase Inhibitors
CA2212326A1 (en) O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
NO20001169L (en) 6.9-bridge erythromycin derivatives
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
NO20002099L (en) 6,11-bridged erythromycin derivative
TW372237B (en) 1-2-4 triazolo[1,5-a]pyrimidines, pharmaceutical compositions containing them for treatment and/or prophylaxis of seizures, neurological disorders and/or conditions in which there is neurological damage, and processes for their preparation
WO2000026224A3 (en) Novel macrolide antibiotics
DE69524428D1 (en) DIHYDROBENZOFURANE AND RELATED COMPOUNDS AS AN ANTI-FLAMMING AGENTS
CA2107223A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
NO20001439L (en) 3'-N-modified 6-O-substituted erythromycin ketolide derivatives with antibacterial activity
NO995033L (en) 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine
CA2597327A1 (en) Antibiotic macrolides
MX9200485A (en) PROCESS FOR OBTAINING DERIVATIVES OF TETRA HIDRO PIRIDINA AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
NO995035L (en) 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds
DE69122858T2 (en) THERAPEUTIC BENZAZEPINE COMPOUNDS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application